Table 2.
Clinical trials investigating CD36 expression.
| No | Conditions | Title | Interventions | Identifier |
|---|---|---|---|---|
| 1 | Healthy Young/Elderly | Effects of Native Whey or Milk Supplementation on Adaptations to 12 Weeks of Strength Training in Young and Elderly | Dietary Supplement: Native whey|Dietary Supplement: Milk|Other: Strength training | NCT03033953 |
| Anabolic Effects of Whey and Casein After Strength Training in Young and Elderly | Strength training|Dietary Supplement: Milk 1%|Dietary Supplement: Whey protein concentrate 80|Dietary Supplement: Native whey | NCT02968888 | ||
|
| ||||
| 2 | Taste Sensitivity|Fatty Acid Type | Fatty Acid Taste Thresholds: Caproic, Lauric, Oleic, Linoleic, Linolenic | NCT01996566 | |
|
| ||||
| 3 | Obesity/Metabolic Syndrome | CD36 and Human Fat Taste Perception | No intervention | NCT02699567 |
| Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans | NCT02126735 | |||
| Study 8: Fat Perception in Humans (09-0873) | NCT01128400 | |||
| Study 19: Metabolically Normal and Metabolically Abnormal Obesity | Behavioral: overfeeding | NCT01184170 | ||
|
| ||||
| 4 | Insulin Resistance|Endothelial Dysfunction | CD36 in Nutrient Delivery and Its Dysfunction | Sildenafil Citrate (Viagra) | NCT03012386 |
|
| ||||
| 5 | Type 2 Diabetes or Obesity Without Diabetes | Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients. | Other: Measure the threshold of detection for linoleic acid|Other: Oral stimulation tests|Other: Venous blood samples|Other: Samples for genetic studies (ancillary study) | NCT02028975 |
|
| ||||
| 6 | Moderate Hypertriacylglycerolemic Subjects | Intervention With n3 LC-PUFA-supplemented Yogurt | Dietary Supplement: n3 long chain polyunsaturated fatty acids | NCT01244048 |
|
| ||||
| 7 | Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention | Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention | Drug: Evolocumab|Drug: Placebo | NCT03258281 |
|
| ||||
| Insulin Resistance|Diabetes|Cancer|Obesity|Inflammation | Study 14: Diet and Metabolic Inflammation | Other: Diet A|Other: Diet B | NCT02539355 | |
|
| ||||
| Renal Failure Chronic Requiring Hemodialysis|Metabolic Syndrome|Diabetes Mellitus Type 2|Hyperlipidemia | Study 16: Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients | Drug: Atorvastatin | NCT01448174 | |
|
| ||||
| Cardiovascular Abnormalities | Study 13: A Study of Immunological Biomarkers as Predictors of Cardiovascular Events | Other: blood tests | NCT02894060 | |
|
| ||||
| Coronary Artery Disease | Polymorphisms in CD36 and STAT3 Genes and Different Dietary Interventions Among Patients With Coronary Artery Disease | Dietary Supplement: Olive oil|Dietary Supplement: Nuts|Dietary Supplement: Control diet | NCT02202265 | |
|
| ||||
| Thrombocytopenia | Study 5: Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus | None | NCT00015639 | |
|
| ||||
| Idiopathic Thrombocytopenic Purpura | The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. | Drug: Eltrombopag|Drug: conventional | NCT03412188 | |
|
| ||||
| Myelodysplastic Syndromes | Study 22: Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes | Azacitidine|Drug: Erythropoietin|Drug: Azacitidine (Monotherapy) | NCT00379912 | |
|
| ||||
| Rheumatoid Arthritis | Study 7: A New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis | Diagnostic Test: Blood test | NCT03216928 | |
|
| ||||
| Rheumatoid Arthritis | Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance | NCT01180361 | ||
|
| ||||
| SLE|Rheumatoid Arthritis|Healthy Subjects | Study 15: Efferocytosis and Genomic Polymorphism in Autoimmune Diseases | NCT00364728 | ||
|
| ||||
| HIV Infections | Study 12: Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers | Drug: Maraviroc | NCT00771823 | |